基因饮食对癌症的影响:来自系统审查和元分析的证据
Majid Kamali1, Masoomeh Ataei Kachooei2, Bahareh Aminnezhad3
1Tabriz University of Medical Sciences, Iran.
Integrative cancer therapies
|March 5, 2026
概括
性饮食 (KD) 显示出作为支持性癌症治疗的承诺,改善代谢健康,身体组成和生活质量. 需要进一步的研究来证实它对治疗并发症的影响.
科学领域:
- 在瘤学瘤学.
- 代谢医学是一种代谢医学.
- 营养科学 营养科学
背景情况:
- 新出现的证据表明,性饮食 (KD) 可能通过增强代谢参数和减轻副作用来帮助癌症治疗.
- 本综述综合了从系统性审查和对KD对癌症患者影响的元分析中获得的数据.
研究的目的:
- 审查性饮食 (KD) 在癌症管理中的影响.
- 专注于代谢结果,身体组成,生活质量和瘤进展.
- 对治疗相关并发症的探索性分析.
主要方法:
- 按照PRISMA指南进行系统审查和元分析.
- 在PubMed,Scopus和Web of Science中搜索相关的系统评论和元分析.
- 分析了24篇符合条件的评论,检查KD对癌症和治疗副作用的影响.
主要成果:
- 性饮食 (KD) 在葡萄糖和甘油三等代谢标志物中表现出改善.
- 在身体组成和患者生活质量方面观察到好处.
- 关于治疗相关并发症,包括放射治疗副作用的证据有限且多样化.
结论:
- 性饮食 (KD) 具有作为癌症治疗中安全有效的辅助疗法的潜力.
- 需要进行额外的研究才能得出关于KD在瘤学中的作用的最终结论.
- 癌症可能提供超出代谢改善的好处,影响患者的整体幸福感.
相关概念视频
Cancer Survival Analysis
806
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
806
Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
Cancer Prevention
8.5K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
8.5K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K


